Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
<b>Background:</b> Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the safety signals of canakinumab by data minin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/114 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587743980421120 |
|---|---|
| author | Weidong Zhang Yunzhou Chen Zeyu Yao Mengling Ouyang Minghui Sun Shupeng Zou |
| author_facet | Weidong Zhang Yunzhou Chen Zeyu Yao Mengling Ouyang Minghui Sun Shupeng Zou |
| author_sort | Weidong Zhang |
| collection | DOAJ |
| description | <b>Background:</b> Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the safety signals of canakinumab by data mining from FAERS. <b>Methods:</b> We used a disproportionate analysis to quantify canakinumab-related adverse events (AEs) using four algorithms. Clinical prioritization of the detected signals was assessed with a semiquantitative score method. Serious and non-serious outcomes were compared by statistical methods. Additionally, a stratification analysis of serious infections was conducted at the system organ class (SOC) level. <b>Results:</b> A total of 28,496 canakinumab-related AEs were collected, and 71 suspicious signals detected. Among these, 19 preferred terms (PTs) were identified as unexpected signals, including deafness, appendicitis, brain oedema, cushingoid, cellulitis, and papilledema. Of the AEs, 16 were more likely reported as serious outcomes, such as pneumonia, abdominal pain, deafness, and infection. Based on clinical priority score, 44 PTs were classified as weak, 27 as moderate, and none as strong. Furthermore, 30 PTs demonstrated a high level of evidence, primarily derived from FDA prescribing information, randomized controlled trials, and systematic reviews. Stratification analysis of infections and infestations (serious outcomes) revealed a stronger association of severe infections with canakinumab in older or heavier individuals. All positive signals followed an early failure pattern, with the incidence of canakinumab-associated AEs decreasing over time. <b>Conclusions:</b> We found that most of the suspicious signals were associated with infections. More attention should be paid to serious infections, particularly in males, individuals aged ≥60 years, or those weighing >100 kg, who demonstrated the highest risk of serious infections. |
| format | Article |
| id | doaj-art-d498735ebd024b31a187e8bafef40d9c |
| institution | Kabale University |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-d498735ebd024b31a187e8bafef40d9c2025-01-24T13:45:26ZengMDPI AGPharmaceuticals1424-82472025-01-0118111410.3390/ph18010114Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)Weidong Zhang0Yunzhou Chen1Zeyu Yao2Mengling Ouyang3Minghui Sun4Shupeng Zou5Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, ChinaDepartment of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China<b>Background:</b> Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential. Thus, we comprehensively evaluated the safety signals of canakinumab by data mining from FAERS. <b>Methods:</b> We used a disproportionate analysis to quantify canakinumab-related adverse events (AEs) using four algorithms. Clinical prioritization of the detected signals was assessed with a semiquantitative score method. Serious and non-serious outcomes were compared by statistical methods. Additionally, a stratification analysis of serious infections was conducted at the system organ class (SOC) level. <b>Results:</b> A total of 28,496 canakinumab-related AEs were collected, and 71 suspicious signals detected. Among these, 19 preferred terms (PTs) were identified as unexpected signals, including deafness, appendicitis, brain oedema, cushingoid, cellulitis, and papilledema. Of the AEs, 16 were more likely reported as serious outcomes, such as pneumonia, abdominal pain, deafness, and infection. Based on clinical priority score, 44 PTs were classified as weak, 27 as moderate, and none as strong. Furthermore, 30 PTs demonstrated a high level of evidence, primarily derived from FDA prescribing information, randomized controlled trials, and systematic reviews. Stratification analysis of infections and infestations (serious outcomes) revealed a stronger association of severe infections with canakinumab in older or heavier individuals. All positive signals followed an early failure pattern, with the incidence of canakinumab-associated AEs decreasing over time. <b>Conclusions:</b> We found that most of the suspicious signals were associated with infections. More attention should be paid to serious infections, particularly in males, individuals aged ≥60 years, or those weighing >100 kg, who demonstrated the highest risk of serious infections.https://www.mdpi.com/1424-8247/18/1/114FAERSadverse eventspharmacovigilancecanakinumabdata mining |
| spellingShingle | Weidong Zhang Yunzhou Chen Zeyu Yao Mengling Ouyang Minghui Sun Shupeng Zou Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) Pharmaceuticals FAERS adverse events pharmacovigilance canakinumab data mining |
| title | Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) |
| title_full | Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) |
| title_fullStr | Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) |
| title_full_unstemmed | Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) |
| title_short | Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) |
| title_sort | post marketing pharmacovigilance of canakinumab from the fda adverse event reporting system faers |
| topic | FAERS adverse events pharmacovigilance canakinumab data mining |
| url | https://www.mdpi.com/1424-8247/18/1/114 |
| work_keys_str_mv | AT weidongzhang postmarketingpharmacovigilanceofcanakinumabfromthefdaadverseeventreportingsystemfaers AT yunzhouchen postmarketingpharmacovigilanceofcanakinumabfromthefdaadverseeventreportingsystemfaers AT zeyuyao postmarketingpharmacovigilanceofcanakinumabfromthefdaadverseeventreportingsystemfaers AT menglingouyang postmarketingpharmacovigilanceofcanakinumabfromthefdaadverseeventreportingsystemfaers AT minghuisun postmarketingpharmacovigilanceofcanakinumabfromthefdaadverseeventreportingsystemfaers AT shupengzou postmarketingpharmacovigilanceofcanakinumabfromthefdaadverseeventreportingsystemfaers |